KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Current Leases (2021 - 2025)

Aurinia Pharmaceuticals' Current Leases history spans 5 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Current Leases fell 92.4% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, down 92.4%, while the annual FY2025 figure was $1.1 million, 92.4% down from the prior year.
  • Current Leases reached $1.1 million in Q4 2025 per AUPH's latest filing, down from $16.3 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $16.3 million in Q3 2025 to a low of $918000.0 in Q3 2022.
  • Average Current Leases over 5 years is $5.3 million, with a median of $1.1 million recorded in 2025.
  • Peak YoY movement for Current Leases: crashed 92.81% in 2024, then soared 1503.87% in 2025.
  • A 5-year view of Current Leases shows it stood at $1.1 million in 2021, then fell by 13.31% to $918000.0 in 2022, then grew by 7.73% to $989000.0 in 2023, then soared by 1320.22% to $14.0 million in 2024, then crashed by 92.4% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Current Leases are $1.1 million (Q4 2025), $16.3 million (Q3 2025), and $16.2 million (Q2 2025).